In a second national prospective observational study of 7,664 anti-TNF-treated patients that used data from the British Society for Rheumatology Biologics Register with severe RA, 19 serious infections with intracellular pathogens were isolated without a preference for either infliximab or adalimumab (Dixon et al., 2006). The gene discussed is TNF; the disease is infection.